Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants

  • Azizollahi, Hamid Reza (Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences) ;
  • Rafeey, Mandana (Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences)
  • Received : 2014.12.18
  • Accepted : 2015.11.26
  • Published : 2016.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Gastroesophageal reflux disease (GERD) occurs in pediatric patients when reflux of gastric contents presents with troublesome symptoms. The present study compared the effects of omeprazole and ranitidine for the treatment of symptomatic GERD in infants of 2-12 months. Methods: This study was a clinical randomized double-blind trial and parallel-group comparison of omeprazole and ranitidine performed at Children Training Hospital in Tabriz, Iran. Patients received a standard treatment for 2 weeks. After 2 weeks, the patients with persistent symptoms were enrolled in this randomized study. Results: We enrolled 76 patients in the present study and excluded 16 patients. Thirty patients each were included in group A (ranitidine) and in group B (omeprazole). GERD symptom score for groups A and B was $47.17{\pm}5.62$ and $51.93{\pm}5.42$, respectively, with a P value of 0.54, before the treatment and $2.47{\pm}0.58$ and $2.43{\pm}1.15$, respectively, after the treatment (P=0.98). No statistically significant differences were found between ranitidine and omeprazole in their efficacy for the treatment of GERD. Conclusion: The safety and efficacy of ranitidine and omeprazole have been demonstrated in infants. Both groups of infants showed a statistically significant decrease in the score of clinical variables after the treatment.

Keywords

References

  1. Khan S, Orenstein SR. Gastroesophageal reflux disease. In: Kliegman RM, Stanton BF, St. Geme JW III, Schor NF, Behrman RE, editors. Nelson textbook of pediatrics. 19th ed. Philadelphia: Elsevier Saunders, 2011:1266-9.
  2. Winter H, Kum-Nji P, Mahomedy SH, Kierkus J, Hinz M, Li H, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr 2010;50:609-18. https://doi.org/10.1097/MPG.0b013e3181c2bf41
  3. Tolia V, Bishop PR, Tsou VM, Gremse D, Soffer EF, Comer GM, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2006;42:384-91. https://doi.org/10.1097/01.mpg.0000214160.37574.d3
  4. Salvatore S, Hauser B, Vandemaele K, Novario R, Vandenplas Y. Gastroesophageal reflux disease in infants: how much is predictable with questionnaires, pH-metry, endoscopy and histology? J Pediatr Gastroenterol Nutr 2005;40:210-5. https://doi.org/10.1097/00005176-200502000-00024
  5. Deal L, Gold BD, Gremse DA, Winter HS, Peters SB, Fraga PD, et al. Age-specific questionnaires distinguish GERD symptom frequency and severity in infants and young children: development and initial validation. J Pediatr Gastroenterol Nutr 2005;41:178-85. https://doi.org/10.1097/01.mpg.0000172885.77795.0f
  6. Wienbeck M, Barnert J. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol Suppl 1989;156:7-13.
  7. Hussain S, Kierkus J, Hu P, Hoffman D, Lekich R, Sloan S, et al. Safety and efficacy of delayed release rabeprazole in 1- to 11- month-old infants with symptomatic GERD. J Pediatr Gastroenterol Nutr 2014;58:226-36.
  8. Sacre L, Vandenplas Y. Gastroesophageal reflux associated with respiratory abnormalities during sleep. J Pediatr Gastroenterol Nutr 1989;9:28-33. https://doi.org/10.1097/00005176-198909010-00006
  9. Rudolph CD, Mazur LJ, Liptak GS, Baker RD, Boyle JT, Colletti RB, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001;32 Suppl 2:S1-31.
  10. Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Lam SK, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005;11:4067-77. https://doi.org/10.3748/wjg.v11.i26.4067
  11. Merki HS, Halter F, Wilder-Smith C, Allemann P, Witzel L, Kempf M, et al. Effect of food on H2-receptor blockade in normal subjects and duodenal ulcer patients. Gut 1990;31:148-50. https://doi.org/10.1136/gut.31.2.148
  12. Teyssen S, Pfuetzer R, Stephan F, Singer MV. Comparison of the effect of a 28-d long term therapy with the proton pump inhibitor pantoprazole with the H2-receptor antagonist ranitidine on intragastric pH in healthy human subjects. Gastroenterology 1995; 108(Suppl 4):A240.
  13. Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs 2013;15:119-31. https://doi.org/10.1007/s40272-013-0012-x
  14. van der Pol RJ, Smits MJ, van Wijk MP, Omari TI, Tabbers MM, Benninga MA. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics 2011;127:925-35. https://doi.org/10.1542/peds.2010-2719
  15. Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993;123:148-54. https://doi.org/10.1016/S0022-3476(05)81561-6
  16. Rafeey M, Khatami GH. Incidence and epidemiology of esophagitis in children admitted to endoscopy unit medical center of children in Tehran. Tehran Univ Med J 2004;62:16-23.
  17. Pettit M. Treatment of gastroesophageal reflux disease. Pharm World Sci 2005;27:432-5. https://doi.org/10.1007/s11096-005-4798-7
  18. Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M. Esomeprazole for the treatment of GERD in infants ages 1-11 months. J Pediatr Gastroenterol Nutr 2012;55:14-20.
  19. Omari T, Davidson G, Bondarov P, Nauclér E, Nilsson C, Lundborg P. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007;45:530-7. https://doi.org/10.1097/MPG.0b013e31812e012f
  20. Omari TI, Haslam RR, Lundborg P, Davidson GP. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr 2007;44:41-4. https://doi.org/10.1097/01.mpg.0000252190.97545.07
  21. Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9 Suppl 1:9-14.
  22. Dettmer A, Vogt R, Sielaff F, Lühmann R, Schneider A, Fischer R. Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Aliment Pharmacol Ther 1998;12:865-72. https://doi.org/10.1046/j.1365-2036.1998.00381.x
  23. Bochenek WJ, Mack ME, Fraga PD, Metz DC. Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. Aliment Pharmacol Ther 2004;20:1105-14. https://doi.org/10.1111/j.1365-2036.2004.02233.x
  24. Bate CM, Keeling PW, O'Morain C, Wilkinson SP, Foster DN, Mountford RA, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut 1990;31:968-72. https://doi.org/10.1136/gut.31.9.968
  25. Sachs G, Shin JM, Besancon M, Prinz C. The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther 1993;7 Suppl 1:4-12.
  26. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9 Suppl 1:3-7.
  27. Li J, Zhao J, Hamer-Maansson JE, Andersson T, Fulmer R, Illueca M, et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006;28:419-27. https://doi.org/10.1016/j.clinthera.2006.03.010
  28. Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009;154:514-20.e4. https://doi.org/10.1016/j.jpeds.2008.09.054
  29. Chen IL, Gao WY, Johnson AP, Niak A, Troiani J, Korvick J, et al. Proton pump inhibitor use in infants: FDA reviewer experience. J Pediatr Gastroenterol Nutr 2012;54:8-14. https://doi.org/10.1097/MPG.0b013e31823890b4

Cited by

  1. ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW vol.54, pp.4, 2017, https://doi.org/10.1590/s0004-2803.201700000-42